INDUSTRY NEWS
From Nov. 1, 2022, China National Medical Products Administration (NMPA) will issue drug registration certificates in electronic version, which is as …
To market over-the-counter (OTC) drugs in China, stakeholders used to obey the same documentation requirements and marketing authorization application…
Editor’s Notes: New drugs in this article refer to Innovative/improved new chemical drugs / biological products that have never been granted marketing…
This is a collection of China’s recent pharmaceutical laws, regulations, policies, and standards, mainly issued by the following authorities: Na…
In China, the marketed drugs have been divided into prescription drugs (Rx drugs) and non-prescription drugs since 2000. Non-prescription drugs, also …
This is a collection of China’s recent pharmaceutical laws, regulations, policies, and standards, mainly issued by the following authorities: National…
Notes: For frequently asked questions concerning technical issues, China Center for Drug Evaluation (CDE) releases answers on its website. This articl…
Chinese Pharmacopoeia is an official collection of drug standards, covering drug development, production, sale, utilization, supervision, and control …
In China, pharmaceutical companies or research institutes with drug registration certificates are drug marketing authorization holders (MAHs). Accordi…
On Aug. 24, China National Medical Products Administration (NMPA) suspended the import, sale, and use of UCB Pharma S.A.’s Levetiracetam Concent…